PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.

@article{Passaro2015PARPIO,
  title={PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.},
  author={Carmela Passaro and Massimiliano Volpe and Ginevra Botta and Eloise Scamardella and Giuseppe Perruolo and D. A. Gillespie and Silvana Libertini and Giuseppe Portella},
  journal={Molecular oncology},
  year={2015},
  volume={9 1},
  pages={
          78-92
        }
}
PARP inhibitors are mostly effective as anticancer drugs in association with DNA damaging agents. We have previously shown that the oncolytic adenovirus dl922-947 induces extensive DNA damage, therefore we hypothesized a synergistic antitumoral effect of the PARP inhibitor olaparib in association with dl922-947. Anaplastic thyroid carcinoma was chosen as model since it is a particularly aggressive tumor and, because of its localized growth, it is suitable for intratumoral treatment with… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2008
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.

  • Expert opinion on therapeutic targets
  • 2012
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

DNA replication fidelity.

  • Annual review of biochemistry
  • 2000
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…